JP2025134707A5 - - Google Patents

Info

Publication number
JP2025134707A5
JP2025134707A5 JP2025085673A JP2025085673A JP2025134707A5 JP 2025134707 A5 JP2025134707 A5 JP 2025134707A5 JP 2025085673 A JP2025085673 A JP 2025085673A JP 2025085673 A JP2025085673 A JP 2025085673A JP 2025134707 A5 JP2025134707 A5 JP 2025134707A5
Authority
JP
Japan
Prior art keywords
δ1γδt
cells
sequence
cell
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025085673A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025134707A (ja
Filing date
Publication date
Priority claimed from JP2021542089A external-priority patent/JP7687952B2/ja
Application filed filed Critical
Publication of JP2025134707A publication Critical patent/JP2025134707A/ja
Publication of JP2025134707A5 publication Critical patent/JP2025134707A5/ja
Pending legal-status Critical Current

Links

JP2025085673A 2018-10-01 2025-05-22 血液腫瘍を治療するための遺伝子操作しているγδ－Ｔ細胞及び遺伝子操作していないγδ－Ｔ細胞に関する組成物及び方法 Pending JP2025134707A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862739822P 2018-10-01 2018-10-01
US62/739,822 2018-10-01
JP2021542089A JP7687952B2 (ja) 2018-10-01 2019-10-01 血液腫瘍を治療するための遺伝子操作しているγδ－Ｔ細胞及び遺伝子操作していないγδ－Ｔ細胞に関する組成物及び方法
PCT/US2019/054132 WO2020072536A1 (en) 2018-10-01 2019-10-01 COMPOSITIONS AND METHODS REGARDING ENGINEERED AND NON- ENGINEERED γδ-Τ CELLS FOR TREATMENT OF HEMATOLOGICAL TUMORS

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2021542089A Division JP7687952B2 (ja) 2018-10-01 2019-10-01 血液腫瘍を治療するための遺伝子操作しているγδ－Ｔ細胞及び遺伝子操作していないγδ－Ｔ細胞に関する組成物及び方法

Publications (2)

Publication Number Publication Date
JP2025134707A JP2025134707A (ja) 2025-09-17
JP2025134707A5 true JP2025134707A5 (cg-RX-API-DMAC7.html) 2026-04-01

Family

ID=68393055

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021542089A Active JP7687952B2 (ja) 2018-10-01 2019-10-01 血液腫瘍を治療するための遺伝子操作しているγδ－Ｔ細胞及び遺伝子操作していないγδ－Ｔ細胞に関する組成物及び方法
JP2025085673A Pending JP2025134707A (ja) 2018-10-01 2025-05-22 血液腫瘍を治療するための遺伝子操作しているγδ－Ｔ細胞及び遺伝子操作していないγδ－Ｔ細胞に関する組成物及び方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2021542089A Active JP7687952B2 (ja) 2018-10-01 2019-10-01 血液腫瘍を治療するための遺伝子操作しているγδ－Ｔ細胞及び遺伝子操作していないγδ－Ｔ細胞に関する組成物及び方法

Country Status (13)

Country Link
US (1) US20210388100A1 (cg-RX-API-DMAC7.html)
EP (1) EP3860645A1 (cg-RX-API-DMAC7.html)
JP (2) JP7687952B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210070330A (cg-RX-API-DMAC7.html)
CN (1) CN113056283A (cg-RX-API-DMAC7.html)
AU (1) AU2019354391A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021006182A2 (cg-RX-API-DMAC7.html)
CA (1) CA3115139A1 (cg-RX-API-DMAC7.html)
EA (1) EA202190926A1 (cg-RX-API-DMAC7.html)
IL (1) IL281922A (cg-RX-API-DMAC7.html)
MX (1) MX2021003745A (cg-RX-API-DMAC7.html)
SG (1) SG11202103235PA (cg-RX-API-DMAC7.html)
WO (1) WO2020072536A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108395482B (zh) 2017-02-08 2021-02-05 西比曼生物科技（香港）有限公司 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
EP3773918A4 (en) 2019-03-05 2022-01-05 Nkarta, Inc. CD19 DIRECTED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN IMMUNOTHERAPY
EP4004049A1 (en) * 2019-07-24 2022-06-01 Regeneron Pharmaceuticals, Inc. Chimeric antigen receptors with mage-a4 specificity and uses thereof
CN113402612A (zh) 2020-03-17 2021-09-17 西比曼生物科技（香港）有限公司 靶向cd19和cd20的联合嵌合抗原受体及其应用
CN113667640B (zh) * 2021-08-27 2022-09-02 广州百暨基因科技有限公司 CAR-γδT细胞的制备方法
WO2023102264A1 (en) * 2021-12-05 2023-06-08 Adicet Therapeutics, Inc. Treatment of b cell malignancies
CN116574194A (zh) * 2022-06-02 2023-08-11 深圳普瑞金生物药业股份有限公司 嵌合抗原受体及其用途
KR20250131823A (ko) 2023-03-31 2025-09-03 아벨제타 인크. Cd20 및 bcma를 표적화하는 이중특이적 키메라 항원 수용체
CN121419987A (zh) * 2023-07-07 2026-01-27 南京传奇生物科技有限公司 蛋白质及其用途

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0315295C1 (pt) * 2002-10-17 2021-05-25 Genmab As anticorpo monoclonal humano isolado, célula hospedeira procariótica, composição farmacêutica, molécula biespecífica, usos de um anticorpo, métodos in vitro de detectar a presença de antígeno de cd20 ou uma célula que expressa cd20 em uma amostra, kit, e, vetor de expressão
CA2569509C (en) * 2004-06-03 2014-08-12 Novimmune S.A. Anti-cd3 antibodies and methods of use thereof
AU2005336093B2 (en) 2004-10-08 2011-02-24 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Adoptive immunotherapy with enhanced T lymphocyte survival
JP2008541758A (ja) * 2005-06-02 2008-11-27 アストラゼネカ エービー Ｃｄ２０に対する抗体およびその使用
MX2010000970A (es) * 2007-07-31 2010-03-09 Regeneron Pharma Anticuerpos humanos contra cd20 humano y metodo para utilizarlos.
WO2010042490A1 (en) 2008-10-06 2010-04-15 Boston Medical Center Corporation A single lentiviral vector system for induced pluripotent (ips) stem cells derivation
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
PT2710123T (pt) 2011-05-19 2017-10-13 Inst De Medicina Molecular Linha celular de linfócitos compreendendo células t gama-delta, método de composição e produção resultante dos mesmos
HK1212240A1 (en) * 2012-09-07 2016-06-10 吉宁特有限公司 Combination therapy of a type ii anti-cd20 antibody with a selective bcl-2 inhibitor
CN107058354A (zh) * 2013-04-01 2017-08-18 科济生物医药（上海）有限公司 编码嵌合抗原受体蛋白的核酸及表达嵌合抗原受体蛋白的t淋巴细胞
EP3060059A4 (en) 2013-10-25 2017-11-01 Board of Regents, The University of Texas System Polyclonal gamma delta t cells for immunotherapy
CN107075480A (zh) 2014-07-09 2017-08-18 Tc生物制药有限公司 γδT细胞及其用途
GB201506423D0 (en) * 2015-04-15 2015-05-27 Tc Biopharm Ltd Gamma delta T cells and uses thereof
BR112017001183A2 (pt) * 2014-07-21 2017-11-28 Novartis Ag tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado
EP3189073B2 (en) * 2014-09-04 2025-06-11 Cellectis Trophoblast glycoprotein (5t4, tpbg) specific chimeric antigen receptors for cancer immunotherapy
IL297773B2 (en) * 2014-11-17 2024-07-01 Adicet Bio Inc Engineered gamma delta t-cells
GB201507368D0 (en) * 2015-04-30 2015-06-17 Ucl Business Plc Cell
NL2014935B1 (en) 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
AU2016274633B2 (en) 2015-06-09 2022-04-21 Gammadelta Therapeutics Ltd Methods for the production of TCR gamma delta+ T cells
EP4286511A3 (en) * 2015-06-12 2024-03-06 Lentigen Technology, Inc. Method to treat cancer with engineered t-cells
SG11201803934YA (en) 2015-11-11 2018-06-28 Intrexon Corp Compositions and methods for expression of multiple biologically active polypeptides from a single vector for treatment of cardiac conditions and other pathologies
US11299708B2 (en) 2016-05-12 2022-04-12 Adicet Bio, Inc. Methods for selective expansion of γδ T-cell populations and compositions thereof
WO2018085690A1 (en) * 2016-11-04 2018-05-11 Bluebird Bio, Inc. Anti-bcma car t cell compositions
JP2019535262A (ja) * 2016-11-11 2019-12-12 オートラス リミテッド キメラ抗原受容体
JP7291396B2 (ja) * 2016-11-22 2023-06-15 ティーシーアール２ セラピューティクス インク． 融合タンパク質を用いたｔｃｒの再プログラミングのための組成物及び方法
WO2018133877A1 (zh) 2017-01-23 2018-07-26 科济生物医药（上海）有限公司 靶向bcma的抗体及其应用
SG10202107136XA (en) * 2017-02-08 2021-07-29 Agency Science Tech & Res Gamma delta t cells and a method of augmenting the tumoricidal activity of the same
GB2562774A (en) 2017-05-25 2018-11-28 Mcdonald Michael Genetic construct
EP3561053A1 (en) * 2018-04-26 2019-10-30 Baylor College of Medicine Immune effector cells and molecular adaptors with an antigen cytokine complex for effective cancer immunotherapy
EP3784256A4 (en) * 2018-04-27 2022-06-29 Baylor College of Medicine Car t cells with one or more interleukins
CN108588023B (zh) * 2018-05-09 2020-02-14 河北森朗生物科技有限公司 一种生产嵌合抗原受体修饰的γδT细胞的方法
CA3112584A1 (en) * 2018-09-17 2020-03-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bicistronic chimeric antigen receptors targeting cd19 and cd20 and their uses

Similar Documents

Publication Publication Date Title
JP2025134707A5 (cg-RX-API-DMAC7.html)
EP1786837B1 (en) Antibodies to dkk-1
JP2022065073A (ja) Ｂｃｍａ結合分子及びその使用方法
JP2024522357A (ja) クローディン１８．２ｔ細胞－抗原カプラーおよびその使用
JP2023139070A5 (cg-RX-API-DMAC7.html)
WO2019129053A1 (zh) 以抗体Fc区为骨架的融合蛋白二聚体及其应用
JP2022501074A5 (cg-RX-API-DMAC7.html)
CN107530419A (zh) 治疗疾病的组合疗法
WO2017148424A1 (zh) 一种pdl-1抗体、其药物组合物及其用途
JP2013063973A (ja) 治療用ヒト抗ｉｌ−１ｒ１モノクローナル抗体
JP2024531409A5 (cg-RX-API-DMAC7.html)
WO2002034292A1 (fr) Agents preventifs ou therapeutiques contre le psoriasis renfermant l'antagoniste de l'il-6 comme substance active
CN110114371A (zh) 嵌合抗原受体
JP2022542559A5 (cg-RX-API-DMAC7.html)
JP2022513321A5 (cg-RX-API-DMAC7.html)
JP2024540275A5 (cg-RX-API-DMAC7.html)
CN117858906A (zh) 与cldn18.2和cd3结合的双特异性结合剂
WO2021088904A1 (zh) 抗人程序性死亡配体-1(pd-l1)的抗体及其用途
JP2025134864A (ja) 抗ケモカイン様受容体１ヒト化抗体及びその治療適用
EP3013858A1 (en) Il-21 binding proteins and uses thereof
JPWO2006046661A1 (ja) インターロイキン−６阻害剤
CN114786723A (zh) 序贯抗cd19疗法
TWI876192B (zh) 人類介白素-4受體α抗體
KR20210060355A (ko) 항-CD300c 단클론 항체를 포함하는 암 예방 또는 치료용 조성물
CN111704671B (zh) Ox40抗体及其在治疗癌症中的应用